Tech Company Financing Transactions
Allay Therapeutics Funding Round
On 9/16/2021, Allay Therapeutics raised $60 million in Series C funding from Arboretum Ventures, Brandon Capital Partners and New Enterprise Associates.
Transaction Overview
Company Name
Announced On
9/16/2021
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series C
Investors
Proceeds Purpose
The proceeds from the Series C will advance the Company's lead candidate, ATX-101, into Phase 2b clinical trials, and support the further development of Allay's platform for ultra-sustained analgesic products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4040 Campbell Ave. 110
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
One global team united behind a mission to transform pain management. Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. We believe an era of stalled innovation for pain management is over.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Gridley
Chief Technical Officer
Patrick Ruane
General Manager
Koon Teu
Vice President
Melinda Morrell
VP - Product Management
Cyndi Lee
VP - Regulatory Affairs
Sharon Hall
VP - Regulatory Affairs
Hans Schulz
Browse more venture capital transactions:
Prev: 9/16/2021: DeepHow venture capital transaction
Next: 9/16/2021: PetFriendly venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs